PSA response


Also found in: Dictionary, Thesaurus, Legal, Encyclopedia.

PSA response

A decrease in the level of prostate-specific antigen (PSA) of at least 50% in a patient receiving treatment for prostate cancer.
See also: response
References in periodicals archive ?
In patients treated with luteinizing hormone-releasing hormone (LHRH) agonist/antagonist monotherapy or who have had an orchidectomy, the addition of total androgen blockade (TAB) with androgen receptor antagonists, such as bicalutamide, can offer modest PSA responses that are short-lived in 30% to 35% of patients.
The first 3 patients have a PSA response rate outside the shown scale of, +2216%, +1233% and +1002%.
6: TROPIC data on objective tumor response (in patients with measurable disease, n=405), PSA response (in evaluable patients, n=654) and pain response (evaluated in patients with high scores for pain and/or analgesia use, n=342).
In patients treated with luteinizing-hormone-releasing hormone agonist monotherapy or who have had an orchidectomy, total androgen blockade (TAB) with testosterone antagonists, such as bicalutamide, can offer PSA responses in 30% to 35% of patients.
However, stratifying patients by PSA response, as defined as a [greater than or equal to]50% PSA decline, correlated with OS, with a median survival of 22 months in patients with a PSA response compared with 16 months in those without a PSA response (p = 0.
Of the nine enrolled patients with hormone refractory prostate cancer, one patient has a complete PSA response ongoing after nine months on study and two had partial PSA responses.
Editor's Note: The researchers concluded that "treatment with metformin is safe in non-diabetic patients, and it yields objective PSA responses and may induce disease stabilization.
The publication reports that in patients evaluable for prostate-specific antigen (PSA) there were seven PSA responses (reductions of greater than 50%), seven disease stabilizations and one disease progression on this regimen of antisense therapy targeting the R2 component of ribonucleotide reductase combined with docetaxel and prednisone.
In this study, we monitored PSA responses in urine and serum, as well as hK2 response in urine, obtained from female-to-male transsexuals undergoing long-term androgenizing treatment with testosterone.
These data presented today affirm that GVAX immunotherapy for prostate cancer used in combination with ipilimumab induces a cellular immune response and that the immune response may be associated with durable objective PSA responses, which we previously reported in June 2007 for the first 12 patients treated in this trial," said Peter K.